Measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplantation (alloHCT) is associated with an increased risk of relapse and death in patients with acute myeloid leukemia (AML). In this interview, Christopher Hourigan, MD, DPhil, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, presents the results of Pre-MEASURE, a multicenter evaluation of the prognostic significance of MRD testing prior to allogeneic transplantation for adult patients with AML in first remission. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.